newsfilter
← Latest News
GlobeNewswire·

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK,